Valproate-induced hyperammonaemic encephalopathy: Review of 14 cases in the psychiatric setting

International Clinical Psychopharmacology

Volumn 22, Issue 6, 2007, Pages 330-337

  Dealberto, Marie José C C ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Astrocytes; Carnitine; Encephalopathy; Glutamine; Hyperammonaemia; Urea cycle disorders; Valproate

Indexed keywords

ALPRAZOLAM; AMMONIA; BENZATROPINE; BIPERIDEN; CARNITINE; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; DOXEPIN; FLUPENTIXOL; GEMFIBROZIL; HALOPERIDOL; IBUPROFEN; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; LORAZEPAM; MECLOZINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TEMAZEPAM; THIORIDAZINE; THYROXINE; TRANYLCYPROMINE; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

AMMONIA BLOOD LEVEL; BRAIN DISEASE; CONSCIOUSNESS DISORDER; DISORIENTATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; HUMAN; HYPERAMMONEMIA; LIVER TOXICITY; MEDLINE; MENTAL DEFICIENCY; MOOD DISORDER; PRIORITY JOURNAL; REVIEW; SYMPTOM;

ANTIMANIC AGENTS; HOSPITALS, PSYCHIATRIC; HUMANS; HYPERAMMONEMIA; NEUROTOXICITY SYNDROMES; VALPROIC ACID;

EID: 34948897998     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3281c61b28     Document Type: Review

References (74)

1. Barrueto F, Hack JB (2001). Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Acad Emerg Med 8:999-1001.
2. Batshaw ML, Brusilow SW (1982). Valproate-induced hyperammonemia. Ann Neurol 11:319-321.
3. Blindauer KA, Harrington G, Morris GL, Ho KC (1998). Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurology 51:292-295.
4. Bogdanovic MD, Kidd D, Briddon A, Duncan JS, Land JM (2000). Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial status epilepticus. J Neurol Neurosurg Psychiatry 69:813-815.
5. Bowden CL (2003). Valproate. Bipolar Disord 5:189-202.
6. Brusilow SW (2002). Hyperammonemic encephalopathy. Medicine 81:240-249.
7. Butterworth RF (1998). Effects of hyperammonaemia on brain function. J Inher Metab Dis 21:S6-S20.
8. Butterworth RF (2002). Glutamate transporters in hyperammonemia. Neurochem Int 41:81-85.
9. Cooper AJL (2001). Role of glutamine in cerebral nitrogen metabolism and ammonia neurotoxicity. Ment Retard Dev Disabil Res Rev 7:280-286.
10. Cooper AJL, Plum F (1987). Biochemistry and physiology of brain ammonia. Physiol Rev 67:440-519.
11. Coppola G, Epifanio G, Auricchio G, Federico RR, Resicato G, Pascotto A (2006). Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev 28:358-365.
12. Coulter DL, Allen RJ (1980). Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy. Lancet 1:1310-1311.
13. De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS, Nordli DR Jr, et al. (1998). L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 39:1216-1225.
14. DeVane CL (2003). Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 37:S25-S42.
15. Elgudin L, Hall Y, Schubert D (2003). Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report. Int J Psychiatry Med 33:91-96.
16. Ellaway CJ, Bennetts B, Tuck RR, Wilcken B (1999). Clumsiness, confusion, coma, and valproate. Lancet 353:1408.
17. Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T (2005). Acute valproate poisoning. Pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol 25:376-380.
18. Eze E, Workman M, Donley B (1998). Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. Psychiatr Serv 49:1358-1359.
19. Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, et al. (2006). Valproic acid induced encephalopathy-19 new cases in Germany from 1994 to 2003-A side effect associated to valproate therapy not only in young children. Seizure 15:443-448.
20. Grover VPB, Dresner MA, Forton DM, Counsell S, Larkman DJ, Patel N, et al. (2006). Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy. World J Gatroenterol 12:2969-2978.
21. Grubben B, De Jonghe P, Cras P, Demey HE, Parizel PM (2004). Valproate-induced hyperammonemic encephalopathy: imaging findings on diffusion-weighted MRI. Eur Neurol 52:178-181.
22. Hamer HM, Knake S, Schomburg U, Rosenow F (2000). Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 54:230-232.
23. Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S (2000). Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 32:1035-1038.
24. Heimberger T (2002). Depakote/Depakene/Depacon (divalproex sodium/valproic acid/valproate sodium). Important drug warning. Abbott Pharmaceutical Division. Safety alerts for drugs, biologics, medical devices, and dietary supplements. Food and Drug Administration www.fda.gov/medwatch/SAFETY/2002/depakote_deardoc.pdf (accessed 31 May 2006).
25. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:682-692.
26. Hennessy MJ, Wiles CM (1996). Lamotrigine encephalopathy. Lancet 347:974-975.
27. Honeycutt D, Callahan K, Rutledge L, Evans B (1992). Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 42:666-668.
28. Horiuchi M, Imamura Y, Nakamura N, Maruyama I, Saheki T (1993). Carbamoylphosphate synthetase deficiency in an adult: deterioration due to administration of valproic acid. J Inherit Metab Dis 16:39-45.
29. Kay JDS, Hilton-Jones D, Hyman N (1986). Valproate toxicity and ornithine carbamoyltransferase deficiency. Lancet 2:1283-1284.
30. Kimmel RJ, Irwin SA, Meyer JM (2005). Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. Int Clin Psychopharmacol 20:57-58.
31. Kramer L, Tribl B, Gendo A, Zauner C, Schneider B, Ferenci P, et al. (2000). Partial pressure in ammonia versus ammonia in hepatic encephalopathy. Hepatology 31:30-34.
32. Latour P, Biraben A, Polard E, Bentue-Ferrer D, Beauplet A, Tribut O, et al. (2004). Drug induced encephalopathy in six epileptic patients: topiramate? Valproate? or both? Hum Psychopharmacol 19:193-203.
33. Leão M (1995). Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. Neurology 45:593-594.
34. Lheureux PER, Penazola A, Zahir S, Gris M (2005). Science review: carnitine in the treatment of valproic acid-induced toxicity. What is the evidence? Crit Care 9:431-440.
35. Lockwood AH (2004). Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis 19:345-349.
36. LoVecchio F, Shriki J, Samaddar RL (2005). L-carnitine was safely administered in the setting of valproate toxicity. Am J Emerg Med 23:321-322.
37. Macritchie KAN, Geddes JR, Scott J, Haslam DRS, Goodwin GM (2007). Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane database Syst Rev (1) 00075320-100000000-02124.
38. Marini AM, Zaret BS, Beckner RR (1988). Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology 38:365-371.
39. Moreno FA, Macey H, Schreiber B (2005). Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study. J Clin Psychiatry 66:555-558.
40. Murphy JV, Marquardt K (1982). Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 39:591-592.
41. Nicolai J, Smith SJ, Keunen RWM (2001). Simultaneous side effects of both clozapine and valproate. Intensive Care Med 27:943.
42. Norenberg MD, Rao KVR, Jayakumar AR (2005). Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis 20:303-318.
43. O'Carroll R (1993). Neuropsychological and neuroimaging aspects of latent hepatic encephalopathy (LHE). Alcohol Alcohol Suppl 2:191-195.
44. Oechsner M, Steen C, Stürenburg HJ, Kohlshütter A (1998). Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry 64:680-682.
45. Ohtani Y, Endo F, Matsuda I (1982). Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 101:782-785.
46. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, et al. (2003). Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 114:188-193.
47. Panikkar GP, Gilman SM (1999). Valproate-induced hyperammonemia in the psychiatric setting: 2 cases. J Clin Psychiatry 60:557-559.
48. Perucca E (2002). Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs 16:695-714.
49. Raby WN (1997). Carnitine for valproic acid-induced hyperammonemia. Am J Psychiatry 154:1168-1169.
50. Raja M, Azzoni A (2002). Valproate-induced hyperammonemia. J Clin Psychopharmacol 22:631-633.
51. Raskind JY, El-Chaar GM (2000). The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34: 630-638.
52. Ratnaike RN, Schapel GJ, Rischbieth RHC, Hoffmann S (1986). Hyperammomaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol 22:100-103.
53. Reif A, Leonhard C, Mössner R, Lesch KP, Fallgatter AJ (2004). Encephalopathy and myoclonus triggered by valproic acid. Prog Neuropsychopharmacol Biol Psychiatry 28:1061-1063.
54. Ricard C, Martin K, Tournier M, Begaud B, Verdoux H (2005). A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder. Encephale 31:98-101.
55. Rottach KG, Weiss-Brummer J, Wieland U, Schmauss M (2000). Valproic acid in prophylaxis of bipolar affective disorder. A case of valproate-induced encephalopathy. Nervenarzt 71:401-403.
56. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J (2006). Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 114:1-7.
57. Settle EC (1995). Valproic acid-associated encephalopathy with coma. Am J Psychiatry 152:1236-1237.
58. Shawcross DL, Balata S, Olde Damink SWM, Hayes PC, Wardlaw J, Marshall I, et al. (2004). Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am J Physiol Gastrointest Liver Physiol 287:G503-G509.
59. Stewart JT (2005). Treatment of valproate-induced hyperammonemia. J Am Geriatr Soc 53:1080.
60. Sztajnkrycer MD (2002). Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40:789-801.
61. Teasdale G, Knill-Jones R, Van der Sande J (1978). Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry 41:603-610.
62. Triggs WJ, Gilmore RL, Millington DS, Cibula J, Bunch TS, Harman E (1997). Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure. Int J Clin Pharmacol Ther 35:353-356.
63. Tripp A, Coşkun T, Çataltepe Ş, Özalp İ (1991). Valproate-induced lethal hyperammonaemic coma in a carrier of ornithine carbamoyltransferase deficiency. J Inher Metab Dis 14:836-837.
64. Tripp JH, Hargreaves T, Anthony PP, Searle JF, Miller P, Leonard JV, et al. (1981). Sodium valproate and ornithine carbamyl transferase deficiency. Lancet 1:1165-1166.
65. Vainstein G, Korzets Z, Pomeranz A, Gadot N (2002). Deepening coma in an epileptic patient: the missing link to the urea cycle. Nephrol Dial Transplant 17:1351-1353.
66. Verbiest HBC, Straver JS, Colombo JP, van der Vijver JCM, van Woerkom TCAM (1992). Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma. Acta Neurol Scand 86:275-279.
67. Verrotti A, Trotta D, Morgese G, Chiarelli F (2002). Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 17:367-373.
68. Vossler DG, Wilensky AJ, Cawthon DF, Kraemer DL, Ojemann LM, Caylor LM, et al. (2002). Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia 43:154-159.
69. Warter JM, Marescaux C, Rumbach L, Micheletti G, Chabrier G, Koehl C, et al. (1983). Role of hyperammonemia in stuporous states induced by sodium valproate. [article in French]. Rev Neurol 139:753-757.
70. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H (2001). Neuropsychological characterization of hepatic encephalopathy. J Hepatol 34:768-773.
71. Wyllie E, Wyllie R, Rothner AD, Erenberg G, Cruse RP (1983). Valproate-induced hyperammonemia in asymptomatic children. Cleve Clin Q 50:275-277.
72. Yehya N, Saldarini CT, Koski ME, Davanzo P (2004). Valproate-induced hyperammonemic encephalopathy. J Am Acad Child Adolesc Psychiatry 43:926-927.
73. Ziyeh S, Thiel T, Spreer J, Klisch J, Schumacher M (2002). Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy. Epilepsia 43:1101-1105.
74. Zwingmann C, Butterworth R (2005). An update on the role of brain glutamine synthesis and its relation to cell-specific energy metabolism in the hyperammonemic brain: further studies using NMR spectroscopy. Neurochem Int 47:19-30.